Clinical Trial Update: Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients [Phase 1]

View source ↗

Summary

Phase 1 ascending multiple-dose study of erenumab (AMG 334) in healthy adults and migraine patients, evaluating safety and pharmacokinetics with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• AIMOVIG (ERENUMAB-AOOE)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2019-01-18